|
|
Article: CANTAB PHARMACEUTICALS REPORTS THIRD QUARTER RESULTS
- Article from:
- PR Newswire
- Article date:
- November 28, 1994
CopyrightCOPYRIGHT 1994 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, England, Nov. 28 /PRNewswire/ -- Cantab Pharmaceuticals plc (Nasdaq: CNTBY) today announced financial results for the third quarter ended September 30, 1994.
Revenues for the third quarter of 1994 totaled pounds sterling 683,000, increasing more than two-fold from 219,000 pounds for the same period in 1993. For both periods, revenues were earned under the collaborative agreement with Baxter Healthcare Corp. (NYSE: BAX) relating to Cantab's LM-CD45 product development program for the prevention of kidney transplant rejection.
Operating expenses for the third quarter of 1994 were 1.7 million pounds, compared to 1.1 million pounds for the same period in 1993. ...